liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Cost-effectiveness of primary cytology and HPV DNA cervical screening
Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Health Sciences, Health Technology Assessment.
Department of Medical Microbiology, Lund University, MAS University Hospital, Malmö, Sweden, Department of Medical Microbiology, Lund University, MAS University Hospital, SE-20502 Malmö, Sweden.
2008 (English)In: International Journal of Cancer, ISSN 0020-7136, Vol. 122, no 2, 372-376 p.Article in journal (Refereed) Published
Abstract [en]

Because cost-effectiveness of different cervical cytology screening strategies with and without human papillomavirus (HPV) DNA testing is unclear, we used a Markov model to estimate life expectancy and health care cost per woman during the remaining lifetime for 4 screening strategies: (i) cervical cytology screening at age 32, 35, 38, 41, 44, 47, 50, 55 and 60, (ii) same strategy with addition of testing for HPV DNA persistence at age 32, (iii) screening with combined cytology and testing for HPV DNA persistence at age 32, 41 and 50, iv) no screening. Input data were derived from population-based screening registries, health-service costs and from a population-based HPV screening trial. Impact of parameter uncertainty was addressed using probabilistic multivariate sensitivity analysis. Cytology screening between 32 and 60 years of age in 3-5 year intervals increased life expectancy and life-time costs were reduced from 533 to 248 US Dollars per woman compared to no screening. Addition of HPV DNA testing, at age 32 increased costs from 248 to 284 US Dollars without benefit on life expectancy. Screening with both cytology and HPV DNA testing, at ages 32, 41 and 50 reduced costs from 248 to 210 US Dollars with slightly increased life expectancy. In conclusion, population-based, organized cervical cytology screening between ages 32 to 60 is highly cost-efficient for cervical cancer prevention. If screening intervals are increased to at least 9 years, combined cytology and HPV DNA screening appeared to be still more effective and less costly. © 2007 Wiley-Liss, Inc.

Place, publisher, year, edition, pages
2008. Vol. 122, no 2, 372-376 p.
Keyword [en]
Cervical cancer, Health economics, Markov model, Organized screening
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-47155DOI: 10.1002/ijc.23124OAI: diva2:268051
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2011-01-11

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Sennfält, Karin
By organisation
Faculty of Health SciencesHealth Technology Assessment
In the same journal
International Journal of Cancer
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 21 hits
ReferencesLink to record
Permanent link

Direct link